- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05465408
Culturally Aware AET Non-Initiation Intervention
Addressing Non-Initiation of Recommended Adjuvant Endocrine Therapy With a Culturally Informed-Intervention
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a single-arm pilot trial to examine the feasibility and acceptability of a patient-centered, evidence-based, culturally competent, nurse-led intervention to encourage breast cancer survivors who have not begun taking adjuvant endocrine therapy (AET) to initiate the medication.
The research study procedures include:
- screening for eligibility
- two individual study intervention sessions
- study assessment follow-up questionnaires
This research study involves two individual sessions with a nurse practitioner which will take place via videoconferencing sessions either in-person or via telephone. Participants will also complete three brief questionnaire packets over the 12-week course of the study.
It is expected that up to 35 people will take part in this research study. The investigators plan to enrich the study sample for patients of a racial and/or ethnic minority in order to ensure the generalizability of the study findings.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jamie M Jacobs, PhD
- Phone Number: 617-643-1777
- Email: jjacobs@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital Cancer Center
-
Contact:
- Jamie M Jacobs, Phd
-
Principal Investigator:
- Jamie M Jacobs, PhD
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Institute
-
Contact:
- Leticia Varella, MD
-
Sub-Investigator:
- Leticia Varella, MD
-
Brighton, Massachusetts, United States, 02135
- Recruiting
- Dana-Farber Cancer Institute at St Elizabeth's Medical Center
-
Contact:
- Leticia Varella, MD
-
Sub-Investigator:
- Leticia Varella, MD
-
Concord, Massachusetts, United States, 01742
- Recruiting
- Emerson Hospital/MGH Cancer Center
-
Contact:
- Jamie M Jacobs, Phd
-
Principal Investigator:
- Jamie M Jacobs, PhD
-
Danvers, Massachusetts, United States, 01923
- Recruiting
- Mass General at North Shore Cancer Center
-
Contact:
- Jamie M Jacobs, Phd
-
Principal Investigator:
- Jamie M Jacobs, PhD
-
Foxboro, Massachusetts, United States, 02035
- Recruiting
- Dana-Farber Brigham Cancer Center - Foxborough
-
Contact:
- Leticia Varella, MD
-
Sub-Investigator:
- Leticia Varella, MD
-
Methuen, Massachusetts, United States, 01844
- Recruiting
- Dana-Farber Cancer Institute - Merrimack Valley
-
Contact:
- Leticia Varella, MD
-
Sub-Investigator:
- Leticia Varella, MD
-
Milford, Massachusetts, United States, 01757
- Recruiting
- Dana-Farber Brigham Cancer Center at Milford Regional Medical Center
-
Contact:
- Leticia Varella, MD
-
Sub-Investigator:
- Leticia Varella, MD
-
Newton, Massachusetts, United States, 02462
- Recruiting
- Mass General at Newton Wellesley Hospital
-
Contact:
- Jamie M Jacobs, Phd
-
Principal Investigator:
- Jamie M Jacobs, PhD
-
Weymouth, Massachusetts, United States, 02190
- Recruiting
- Dana-Farber Brigham Cancer Center with South Shore Hospital
-
Contact:
- Leticia Varella, MD
-
Sub-Investigator:
- Leticia Varella, MD
-
-
New Hampshire
-
Londonderry, New Hampshire, United States, 03053
- Recruiting
- Dana-Farber/New Hampshire Onoclogy-Hematology
-
Contact:
- Leticia Varella, MD
-
Sub-Investigator:
- Leticia Varella, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female
- Age 21 or older
- Diagnosis of early-stage (Stage 0-IIIB), hormone receptor-positive breast cancer
- Recommended to start AET at least 3 weeks prior and not currently taking AET OR recommended to start AET in the future and reports hesitations to start AET as determined by a score of >/= 4 (range =0-10) when asked "How hesitant are you about starting your recommended hormonal therapy? (0=Not at all hesitant and 10 = Extremely hesitant)"
- Ability to read and respond in English or Spanish
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- For at least 10 participants, identify as a member of a racial or ethnic minority community per self-report
Exclusion Criteria:
- Uncontrolled psychosis, active suicidal ideation, psychiatric hospitalization within the past year
- Cognitive impairment that prohibits participation in the study
- Undergoing primary treatment for other cancer (i.e., advanced stage cancer)
- Participating in a clinical trial involving AET
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention
Participants will have two (2), 60 minute, individual sessions with a nurse practitioner via videoconferencing (in person or via telephone) and complete three (3) questionnaires at the time of enrollment, 1-month post-baseline, and 3-months post-baseline.
|
One-to-One virtual (videoconference) behavioral intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Program Feasibility
Time Frame: Up to 3 months/12 weeks
|
Feasibility will be demonstrated by enrollment (>50% of eligible and approached patients will enroll), retention (>70% of enrolled participants will complete the two intervention sessions) and attendance (≥70% of participants completing at least one session).
|
Up to 3 months/12 weeks
|
Program Acceptability
Time Frame: Up to 3 months/12 weeks
|
Acceptability will be demonstrated by >75% of participants reporting average satisfaction scores greater than the mid-point of the Client Satisfaction Questionnaire.
The total score range is 3-12, with higher scores indicating a better outcome.
|
Up to 3 months/12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adjuvant endocrine therapy (AET) Initiation
Time Frame: Baseline (within 1-week of consent), 1-month, and 3-months post-baseline
|
Following the intervention, participants will be more likely to have started their AET.
AET initiation will be measured by self-reported questionnaire.
|
Baseline (within 1-week of consent), 1-month, and 3-months post-baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jamie M Jacobs, PhD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States